Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Kreuzer, K; Reiter, A; Birkl-Töglhofer, AM; Dalkner, N; Mörkl, S; Mairinger, M; Fleischmann, E; Fellendorf, F; Platzer, M; Lenger, M; Färber, T; Seidl, M; Birner, A; Queissner, R; Mendel, LS; Maget, A; Kohlhammer-Dohr, A; Häussl, A; Wagner-Skacel, J; Schöggl, H; Amberger-Otti, D; Painold, A; Lahousen-Luxenberger, T; Leitner-Afschar, B; Haybaeck, J; Habisch, H; Madl, T; Reininghaus, E; Bengesser, S.
The PROVIT Study-Effects of Multispecies Probiotic Add-on Treatment on Metabolomics in Major Depressive Disorder-A Randomized, Placebo-Controlled Trial.
Metabolites. 2022; 12(8): Doi: 10.3390/metabo12080770 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Kreuzer Kathrin
Madl Tobias
Reininghaus Eva
Co-Autor*innen der Med Uni Graz
Amberger-Otti Daniela
Bengesser Susanne
Birkl-Töglhofer Anna Maria
Birner Armin
Dalkner Nina
Fellendorf Frederike
Fleischmann Eva
Habisch Hansjörg
Häussl Alfred Alois
Haybäck Johannes
Kohlhammer-Dohr Alexandra
Lahousen-Luxenberger Theresa
Lenger Melanie
Maget Alexander
Mairinger Marco
Mörkl Sabrina
Painold Annamaria
Platzer Martina
Queissner Robert
Schöggl Helmut
Seidl Matthias
Wagner-Skacel Jolana

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

The gut-brain axis plays a role in major depressive disorder (MDD). Gut-bacterial metabolites are suspected to reduce low-grade inflammation and influence brain function. Nevertheless, randomized, placebo-controlled probiotic intervention studies investigating metabolomic changes in patients with MDD are scarce. The PROVIT study (registered at NCT03300440) aims to close this scientific gap. PROVIT was conducted as a randomized, single-center, double-blind, placebo-controlled multispecies probiotic intervention study in individuals with MDD (n = 57). In addition to clinical assessments, metabolomics analyses (1H Nuclear Magnetic Resonance Spectroscopy) of stool and serum, and microbiome analyses (16S rRNA sequencing) were performed. After 4 weeks of probiotic add-on therapy, no significant changes in serum samples were observed, whereas the probiotic groups' (n = 28) stool metabolome shifted towards significantly higher concentrations of butyrate, alanine, valine, isoleucine, sarcosine, methylamine, and lysine. Gallic acid was significantly decreased in the probiotic group. In contrast, and as expected, no significant changes resulted in the stool metabolome of the placebo group. Strong correlations between bacterial species and significantly altered stool metabolites were obtained. In summary, the treatment with multispecies probiotics affects the stool metabolomic profile in patients with MDD, which sets the foundation for further elucidation of the mechanistic impact of probiotics on depression.

Find related publications in this database (Keywords)
NMR spectroscopy
randomized controlled trial
© Med Uni Graz Impressum